Edition:
United Kingdom

UCB Announces Positive CHMP Opinion For Cimzia®


Friday, 27 Apr 2018 

April 27 (Reuters) - UCB SA ::UCB ANNOUNCES POSITIVE CHMP OPINION FOR CIMZIA® (CERTOLIZUMAB PEGOL) IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS.EUROPEAN COMMISSION’S ENDORSEMENT OF CHMP POSITIVE OPINION FOR PSORIASIS EXPECTED IN Q2.CHMP POSITIVE OPINION IS BASED ON DATA FROM A PHASE 3 CLINICAL DEVELOPMENT PROGRAM CONSISTING OF CIMPASI-1, CIMPASI-2 AND CIMPACT.THIS WOULD FURTHER BROADEN CLINICAL VALUE OF CIMZIA.